Japanese Bridging Study Conducted in the United States

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Hepatitis C Virus
Interventions
DRUG

BMS-791325

Capsules, Oral, 300 mg, Single Dose, One day

DRUG

BMS-791325

Capsules, Oral, 900 mg, Single Dose, One day

DRUG

BMS-791325

Capsules, Oral, ≤1200 mg, Single Dose, One day

DRUG

BMS-791325

Capsules, Oral, 300 mg, Every 12 hours, 14 days

DRUG

BMS-791325

Capsules, Oral, 900 mg, once daily 14 days

DRUG

BMS-791325

Capsules, Oral, ≤1200 mg, Every 12 hours or once daily, 14 days

DRUG

Placebo

Capsules, Oral, Single Dose, One day

DRUG

Placebo

Capsules, Oral, Every 12 hours, 14 days

DRUG

Placebo

Capsules, Oral, Once Daily, 14 days

DRUG

Placebo

Capsules, Oral, Every 12 hours or once daily, 14 days

Trial Locations (1)

90630

Local Institution, Cypress

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY